NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT04922021,An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.,https://clinicaltrials.gov/study/NCT04922021,,COMPLETED,"This is a clinical study in adult participants with moderate to severe atopic dermatitis (AD).

The purpose of the study is to test a new medicine (LEO 138559) given by injection to see if it works to treat AD and what the side effects are when compared with a placebo injection with no medical ingredient.

The study will last up to 36 weeks for each participant. The study will include a treatment period of 16 weeks, during which the participants will receive the injections, followed by a period of 16 weeks without treatment with the main purpose of continuing safety evaluations. The participants will regularly visit the clinic for tests and the study doctor will evaluate their AD. The participants will also be asked to answer questions about their AD symptoms and quality of life.",YES,Atopic Dermatitis,DRUG: LEO 138559|DRUG: LEO 138559 placebo,"Change in EASI Score From Baseline to Week 16, The Eczema Area and Severity Index (EASI) is a validated measure used in clinical trials to evaluate the extent and severity of atopic dermatitis. EASI is a composite score ranging from 0 to 72 with higher scores indicating a more extensive and/or severe condition., Week 0 to Week 16","Number of Treatment-emergent Adverse Events From Baseline to Week 16 Per Subject, Week 0 to Week 16",,LEO Pharma,,ALL,ADULT,PHASE2,58,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",LP0145-1376|2020-005541-16,2021-07-14,2022-06-02,2022-09-26,2021-06-10,2023-06-02,2023-07-24,"LEO Pharma Investigational Site, Birmingham, Alabama, 35209, United States|LEO Pharma Investigational Site, Fountain Valley, California, 92708, United States|LEO Pharma Investigational Site, Los Angeles, California, 90045, United States|LEO Pharma Investigational Site, Doral, Florida, 33122, United States|LEO Pharma Investigational Site, Hialeah, Florida, 33012, United States|LEO Pharma Investigational Site, Markham, Ontario, L3P 1X3, Canada|LEO Pharma Investigational Site, Mississauga, Ontario, L5H 1G9, Canada|LEO Pharma Investigational Site, Peterborough, Ontario, K9J 5K2, Canada|LEO Pharma Investigational Site, Berlin, 10117, Germany|LEO Pharma Investigational Site, Dresden, 01307, Germany|LEO Pharma Investigational Site, Leipzig, 04103, Germany|LEO Pharma Investigational Site, Lübeck, 23538, Germany|LEO Pharma Investigational Site, Krakow, 30-033, Poland|LEO Pharma Investigational Site, Kraków, 31-011, Poland|LEO Pharma nvestigational Site, Rzeszów, 35-055, Poland|LEO Pharma Investigational Site, Warszawa, 02-625, Poland|LEO Pharma Investigational Site, Wrocław, 51-685, Poland","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/21/NCT04922021/Prot_SAP_000.pdf"
